We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-5.74%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.49B
AUM Growth
-$345M
Cap. Flow
-$1.43B
Cap. Flow %
-31.97%
Top 10 Hldgs %
44.77%
Holding
117
New
16
Increased
17
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$76.9M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$73.8M
3
AHCO icon
AdaptHealth
AHCO
+$54.6M
4
ACH
Accendra Health
ACH
+$48.2M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$47.9M

Top Sells

Rank Stock Value
1
PHR icon
Phreesia
PHR
+$44.2M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$42M
3
IMGN
Immunogen Inc
IMGN
+$31.5M
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$24.6M
5
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$23.7M

Sector Composition

Rank Sector Weight
1 Healthcare 62.79%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$522M 11.63%
19,991,024
– –
NBIX icon
2
Neurocrine Biosciences
NBIX
$17.2B
$177M 3.94%
1,744,714
+232,000
+15% +$24.1M
CPRX
3
DELISTED
Catalyst Pharmaceutical
CPRX
$172M 3.83%
10,355,099
+4,470,651
+76% +$73.8M
VTRS icon
4
Viatris
VTRS
$20.1B
$163M 3.63%
16,935,997
+6,935,997
+69% +$76.9M
AHCO icon
5
AdaptHealth
AHCO
$1.49B
$132M 2.94%
10,594,914
+2,968,000
+39% +$54.6M
AMED
6
DELISTED
Amedisys
AMED
$109M 2.43%
1,483,179
+347,099
+31% +$30M
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$80.6M 1.8%
5,218,638
+2,869,410
+122% +$47.9M
LRMR icon
8
Larimar Therapeutics
LRMR
$384M
$76.7M 1.71%
16,941,357
– –
SPRY icon
9
ARS Pharmaceuticals
SPRY
$695M
$72.1M 1.61%
11,077,927
– –
CNC icon
10
Centene
CNC
$32.8B
$68M 1.51%
1,075,000
+510,000
+90% +$36.2M
SILK
11
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$67.5M 1.51%
1,725,640
+329,000
+24% +$16.1M
AMLX icon
12
Amylyx Pharmaceuticals
AMLX
$1.97B
$58.2M 1.3%
1,984,333
-708,667
-26% -$24.6M
ACH
13
Accendra Health
ACH
$266M
$56.3M 1.25%
3,867,455
+2,688,455
+228% +$48.2M
MIRM icon
14
Mirum Pharmaceuticals
MIRM
$7.25B
$48.8M 1.09%
2,032,335
– –
BKD icon
15
Brookdale Senior Living
BKD
$3.58B
$48.4M 1.08%
16,406,047
+3,726,396
+29% +$10.7M
EHAB
16
DELISTED
Enhabit
EHAB
$47.3M 1.05%
3,398,746
+402,746
+13% +$5.79M
HLVX
17
DELISTED
HilleVax
HLVX
$46.8M 1.04%
2,833,690
+139,589
+5% +$2.23M
MRUS
18
DELISTED
Merus
MRUS
$43.8M 0.98%
2,380,438
– –
CMAX
19
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$42.3M 0.94%
528,703
– –
SWTX
20
DELISTED
SpringWorks Therapeutics
SWTX
$40.7M 0.91%
1,579,349
+546,349
+53% +$16M
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$39.7M 0.89%
+734,000
New +$35.5M
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$36.6M 0.82%
1,504,578
-1,920,274
-56% -$42M
NAMS icon
23
NewAmsterdam Pharma
NAMS
$3.7B
$33.6M 0.75%
2,535,723
+55,524
+2% +$701K
COGT icon
24
Cogent Biosciences
COGT
$6.68B
$32M 0.71%
2,966,345
– –
EOLS icon
25
Evolus
EOLS
$377M
$30.2M 0.67%
3,569,000
+250,000
+8% +$2.26M
1
2 3 4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q1 2023 Portfolio in Review

As of Q1 2023, Deerfield Management held 117 positions worth $4.49B, down 7.1% from $4.83B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Deerfield Management withdrew a net $1.43B in Q1 2023, closing 11 positions and reducing 12 holdings. Its most notable exit was Phreesia, an estimated $44.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 56% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Intra-Cellular Therapies Inc. worth $39.7M.

  • Deerfield Management's largest Q1 2023 buy was Intra-Cellular Therapies Inc.: 734,000 shares worth $39.7M.
  • Deerfield Management added most to Viatris in Q1 2023, an estimated $76.9M increase.
  • Deerfield Management's biggest Q1 2023 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $42M.
  • Deerfield Management fully exited Phreesia in Q1 2023, selling an estimated $44.2M.
  • Deerfield Management's ten largest holdings make up 45% of its $4.49B portfolio in Q1 2023.
  • Deerfield Management opened 16 new positions and closed 11 in Q1 2023.
  • Deerfield Management's portfolio value fell 7.1% quarter-over-quarter to $4.49B.

Based on Deerfield Management's 13F filing for Q1 2023, filed 15 May 2023.